- Home
- UPXI vs BRNS Comparison
UPXI vs BRNS Comparison
Compare UPXI & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$0.96
HOLD
Current Price
$0.56
Company Overview
Basic Information| Metric | UPXI | BRNS |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 55.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UPXI | BRNS |
|---|---|---|
| Price | $0.96 | $0.56 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $2.00 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 5.9M | 67.7K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.49 | 18.85 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $15,811,345.00 | $14,969,000.00 |
| Revenue This Year | $118.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.18 | ★ N/A |
| Revenue Growth | N/A | ★ 1766.46 |
| 52 Week Low | $0.54 | $0.56 |
| 52 Week High | $22.53 | $2.91 |
Technical Indicators
Market Signals| Indicator | UPXI | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 45.56 | 36.40 |
| Support Level | $0.54 | $0.56 |
| Resistance Level | $2.46 | $0.76 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 63.22 | 1.43 |
Price Performance
Historical Comparison UPXI
BRNS
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via Solana. Geographically, the company generates the majority of its revenue from the United States.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.